Alnylam Pharmaceuticals Inc (ALNY)vsUnicycive Therapeutics Inc (UNCY)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
UNCY
Unicycive Therapeutics Inc
$6.65
+4.07%
HEALTHCARE · Cap: $137.33M
Smart Verdict
WallStSmart Research — data-driven comparison
ALNY leads profitability with a 8.5% profit margin vs 0.0%. ALNY earns a higher WallStSmart Score of 49/100 (D+).
ALNY
Hold49
out of 100
Grade: D+
UNCY
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Intrinsic value data unavailable for UNCY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : UNCY
The strongest argument for UNCY centers on Debt/Equity.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : UNCY
The primary concerns for UNCY are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while UNCY is a value play — different risk/reward profiles.
UNCY carries more volatility with a beta of 1.82 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (49/100 vs 21/100) and 84.9% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Unicycive Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Unicycive Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to transforming the landscape of kidney disease treatment, particularly in addressing hyperphosphatemia and its associated disorders. With its innovative pipeline aimed at regulating phosphorus levels through unique therapeutic mechanisms, Unicycive seeks to improve patient outcomes significantly. The company's strong focus on research and development, coupled with strategic collaborations, positions it well to lead advancements in nephrology care. As Unicycive progresses through its clinical trials, it presents a compelling investment opportunity for institutional investors looking to capitalize on growth in the evolving healthcare sector.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?